|
|
 |
|
Viewing report
|
|
|
|
Biopharma Quarter: Key Trends and Events of the Third Quarter of 2009
Decision Resources, Inc., Dec 2009, Pages: 37
The rules of the game in healthcare are changing. Although U.S. healthcare reform has yet to coalesce, the European Union is cracking down on generics shipments, stirring up controversy about trade rules and counterfeit drugs, and ratcheting up its oversight of antitrust laws, launching an investigation into purported agreements between a pharma company and generics manufacturers to keep generic alternatives off the market. Companies are looking outside of their traditional strongholds and toward new opportunities in emerging geographical markets, niche diseases, and targeted approvals.
Questions Answered in This Report
- Healthcare reform initiatives in the United States and related global moves toward cost-containment intensified in the third quarter. What is the outlook for U.S. healthcare reform as the issue becomes more heated? What are the implications for the generics drug business? How do these changes shape the emerging personalized medicine business model? How must pharma companies adapt to become winners in a new marketplace?
- Dealmaking activity increased slightly in the third quarter of 2009 relative to the prior quarter. Which companies were most active? What trends in dealmaking illustrate company strategies?
- Emerging geographical markets are of great interest to makers of branded and generic pharmaceuticals. How are companies gaining access to these markets? What are some of the challenges of reaching these markets?
- The 2006 U.S. approval of a vaccine against human papillomavirus, for use in young girls with the goal of warding off HPV and consequent cervical cancer, was controversial. How has that vaccine been received?
What events have occurred since that initial approval? How are commercial dynamics related to this marketplace evolving?
Scope
- Events: Genetic testing, personalized medicine, companion diagnostics, testing uptake; Genzyme’s troubles; HPV vaccine approvals; HIV vaccine development.
- Dealmaking: Companies, deal values, historical comparisons, trends, technologies, products.
- Generics: Watson expands, Wockhardt contracts; EU generic shipment seizures; legislative defi nition loopholes; EC antitrust investigations; U.K. generic substitution plans.
- Healthcare reform: Rational scenarios; winners and losers; size, scale, and focus of companies before and after reform.
Customers who bought this item also bought
Biotech Investment and Business Trends: Weathering the Economic Storm
Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008
Biotechnology in India - An Indian Market Report
Executing Change: Survival Strategies of Big Biotech
Antiviral Therapeutics - Technologies, Markets and Companies
Animal Biotechnology - Technologies, Markets and Companies
Biotech Investment and Business Trends: Surviving the Long Road to Market
Biotechnology - Global Outlook
Top 50 Biotechnology Companies & Their Pipelines 2011
Biotech 2010 Life Sciences: Adapting for Success
|
|
|
|
